◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › R › REGN

Regeneron Pharmaceuticals Inc (REGN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-08-29

Regeneron Pharmaceuticals Inc (REGN) operates in the Biotechnology industry and is headquartered in Tarrytown, United States with about 15,410 employees. Its market capitalization is roughly $81 billion. In the fiscal year ended 2025-12-31, REGN reported $14.3B in revenue and $4.5B in net income.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Interactive charts & full statements → Open the REGN valuation workbench →

REGN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$15.5B	$14.3B	$14.2B	$13.1B	$12.2B	$16.1B	$8.5B	$7.9B	$6.7B	$5.9B	$4.9B	$4.1B	$2.8B	$2.1B	$1.4B	$446M	$459M	$379M	$238M	$125M	$63M
Gross Profit	$13.2B	$12.2B	$12.2B	$12.2B	$10.5B	$13.3B	$7.1B	$7.1B	$6.3B	$5.5B	$4.6B	$3.7B	$2.6B	$1.9B	$1.3B	$442M	$457M	$363M	$238M	$125M	$41M
Gross Margin %	84.9%	85.4%	86.1%	93.3%	86.0%	83.0%	84.0%	90.0%	93.5%	93.2%	93.8%	90.4%	92.7%	92.6%	93.9%	99.1%	99.5%	95.8%	99.6%	100.0%	64.2%
Operating Income (EBIT)	$4.0B	$3.6B	$4.0B	$4.0B	$5.4B	$8.9B	$3.6B	$2.2B	$2.5B	$2.1B	$1.3B	$1.3B	$838M	$760M	$458M	($205M)	($97M)	($74M)	($90M)	($114M)	($107M)
Operating Margin %	25.6%	24.9%	28.1%	30.9%	44.2%	55.7%	42.1%	28.1%	37.8%	35.4%	27.4%	30.5%	29.7%	36.1%	33.2%	-46.0%	-21.2%	-19.5%	-37.7%	-91.5%	-169.1%
Net Income	$4.3B	$4.5B	$4.4B	$4.0B	$4.3B	$8.1B	$3.5B	$2.1B	$2.4B	$1.2B	$896M	$636M	$348M	$424M	$750M	($222M)	($104M)	($68M)	($83M)	($106M)	($102M)
Net Margin %	27.9%	31.4%	31.1%	30.1%	35.6%	50.2%	41.3%	26.9%	36.4%	20.4%	18.4%	15.5%	12.3%	20.2%	54.4%	-49.7%	-22.8%	-17.9%	-34.7%	-84.5%	-161.3%
EBITDA	$5.8B	$5.8B	$5.3B	$4.0B	$5.3B	$9.7B	$4.1B	$2.4B	$2.7B	$2.2B	$1.4B	$1.3B	$891M	$801M	$495M	($174M)	($78M)	($55M)	($79M)	($82M)	($77M)
Earnings Per Share (EPS)	$40.37	$41.48	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.29	$10.34	$7.70	$5.52	$3.07	$3.81	$6.50	$-2.45	$-1.26	$-0.85	$-1.05	$-1.59	$-1.77
Shares Outstanding (M)	107M	109M	115M	114M	114M	112M	115M	115M	115M	116M	116M	115M	113M	111M	115M	91M	83M	80M	79M	66M	58M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$4.3B	$3.6B	$3.9B	$3.8B	$3.7B	$3.0B	$3.8B	$3.7B
Gross Profit	$3.7B	$2.9B	$3.3B	$3.2B	$3.1B	$2.6B	$3.2B	$3.2B
Gross Margin %	86.6%	81.4%	85.0%	86.1%	85.6%	84.7%	85.1%	86.8%
Operating Income (EBIT)	$1.4B	$643M	$880M	$1.0B	$1.1B	$592M	$990M	$1.2B
Operating Margin %	33.1%	17.8%	22.7%	27.4%	29.4%	19.5%	26.1%	31.7%
Net Income	$1.3B	$727M	$845M	$1.5B	$1.4B	$809M	$918M	$1.3B
Net Margin %	30.2%	20.2%	21.7%	38.9%	37.9%	26.7%	24.2%	36.0%
EBITDA	$1.7B	$967M	$1.2B	$1.9B	$1.7B	$1.0B	$1.1B	$1.6B
Earnings Per Share (EPS)	$12.14	$6.75	$7.86	$13.62	$12.81	$7.27	$8.06	$11.54
Shares Outstanding (M)	107M	108M	108M	107M	109M	111M	114M	116M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$4.4B	$5.0B	$4.4B	$4.6B	$5.0B	$7.1B	$2.6B	$2.4B	$2.2B	$1.3B	$1.5B	$1.3B	$752M	$589M	($75M)	($142M)	$96M	($72M)	($89M)	$27M	$23M
Capital Expenditures (CapEx)	$921M	$898M	$756M	$926M	$590M	$552M	$615M	$430M	$383M	$273M	$512M	$678M	$333M	$156M	$49M	$57M	$100M	$97M	$35M	$18M	$3M
Free Cash Flow (FCF)	$3.5B	$4.1B	$3.7B	$3.7B	$4.4B	$6.5B	$2.0B	$2.0B	$1.8B	$1.0B	$974M	$653M	$419M	$432M	($124M)	($199M)	($3M)	($170M)	($124M)	$9M	$20M
FCF Margin %	22.7%	28.4%	25.8%	28.0%	36.4%	40.6%	23.6%	25.4%	27.0%	17.6%	20.0%	15.9%	14.9%	20.5%	-9.0%	-44.6%	-0.7%	-44.7%	-52.0%	7.1%	31.9%
Dividends Paid	$378M	$370M	$0M	$0M	—	—	—	—	—	$359M	$500M	$547M	$295M	$0M	$0M	$0M	$0M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$574M	$1.1B	$1.2B	$1.6B	$1.1B	$1.0B	$1.3B	$1.3B
Capital Expenditures (CapEx)	$240M	$231M	$249M	$201M	$177M	$272M	$267M	$184M
Free Cash Flow (FCF)	$334M	$848M	$922M	$1.4B	$968M	$774M	$996M	$1.1B
FCF Margin %	7.8%	23.5%	23.7%	37.8%	26.3%	25.5%	26.3%	29.8%
Dividends Paid	$97M	$98M	$93M	$91M	$93M	$94M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$41.7B	$40.6B	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B	$14.8B	$11.7B	$8.8B	$7.0B	$5.6B	$3.9B	$3.0B	$2.1B	$1.3B	$1.1B	$741M	$670M	$936M	$585M
Cash & Cash Equivalents	$2.5B	$3.1B	$2.5B	$2.7B	$3.1B	$2.9B	$2.2B	$1.6B	$1.5B	$813M	$535M	$809M	$649M	$536M	$230M	$484M	$113M	$207M	$248M	$499M	$238M
Total Liabilities	$10.0B	$9.3B	$8.4B	$7.1B	$6.5B	$6.7B	$6.1B	$3.7B	$3.0B	$2.6B	$2.5B	$2.0B	$1.3B	$999M	$835M	$838M	$562M	$344M	$251M	$476M	$368M
Total Debt (Short + Long-Term)	$2.0B	$2.0B	$2.0B	$2.0B	$2.7B	$2.7B	$3.6B	$0M	$91M	$1.2B	$481M	$816M	$497M	$321M	$298M	$276M	$160M	$109M	$162M	$200M	$221M
Total Shareholders' Equity	$31.7B	$31.3B	$29.4B	$26.0B	$22.7B	$18.8B	$11.0B	$11.1B	$8.8B	$6.1B	$4.4B	$3.7B	$2.5B	$2.0B	$1.2B	$486M	$528M	$397M	$419M	$460M	$217M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive REGN viewer.

REGN Metric Deep Dives

Other Companies in Biotechnology

BLUEJET · Blue Jet Healthcare Limited — ₹100 billion
1177 · Sino Biopharmaceutical Limited — HK$97 billion
1548 · Genscript Biotech Corporation — HK$90 billion
9926 · Akeso, Inc. — HK$83 billion
SUPRIYA · Supriya Lifescience Limited — ₹73 billion
MRNA · Moderna — $61 billion
6821 · Asymchem Laboratories (Tianjin) Co., Ltd. — HK$59 billion
3759 · Pharmaron Beijing Co., Ltd. — HK$54 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← REGL All “R” companies REGS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.